Event Recordings

Day 1  |  Day 2

Day 1: Monday, April 24, 2023

Session I: Fireside Chat with Robert Califf, MD, FDA Commissioner

Moderator: Robert Harrington, MD

Robert Califf, MD, MACC
FDA Commissioner

Session II: Drug Development I

Moderator: Sandra Horning, MD

Human Genetics & Drug Discovery

Andrew Plump, MD, PhD
President, R&D, Takeda Pharmaceutical Co­­mpany

Leading Design for Breakthrough Therapies and Vaccines

Mikael Dolsten, MD, PhD
CSO and President, Worldwide Research, Development and Medical, Pfizer

From Data to Insights to Impact

How Data Science is Central to Discovering and Developing Medicines

Najat Khan, PhD
Chief Data Science Officer & Global Head, Strategy and Operations, R&D, Janssen Pharmaceutical Companies of Johnson & Johnson

Enabling drug discovery innovation through a global open access platform

Steve Yang, PhD
Co-CEO, WuXi AppTec

Session II: Panel Discussion

Session III: Funding Drug Development

Session III: Panel Discussion

Moderator: Mathai Mammen, MD, PhD


Jim Tananbaum, MD
CEO and Founder, Foresite Capital Management, LLC

Monica Beam, PhD
Senior Vice President, Science & Technology, Alexandria Real Estate Equities, Inc/Alexandria Venture Investments

Lip-Bu Tan, MBA
Managing Partner, Walden Catalyst

Joshua Bleharski, PhD
Managing Director, Healthcare Investment Banking, J.P. Morgan

Session IV: Presentation of Lifetime Achievement Award

Moderator: Levi Garraway, MD, PhD

Imatinib as a Paradigm of Targeted Cancer Therapies

Brian Druker, MD
Director, OHSU Knight Cancer Institute
Professor of Medicine, Division of Hematology/Medical Oncology, School of Medicine, OHSU

Session V: Drug Development II

Moderator: Helen Blau, PhD

What Could be Better Than Disease Prevention?

Hal Barron, MD
CEO, Altos Labs

Using Big Data to Develop Therapeutic Signatures of Response for Cancer

George Sledge, Jr., MD
Executive Vice President and CMO, Caris Life Sciences

Reimagining Pharmacovigilance

Aida Habtezion, MD
CMO and Head of Worldwide Medical & Safety, Pfizer

Drug Discovery in the Modern Era

Mathai Mammen, MD, PhD
CEO Designate, FogPharma; Former Executive Vice President, Pharmaceuticals, R&D, Johnson & Johnson

Session V: Panel Discussion

Session VI: CEO Fireside Chat

Moderator: Lloyd Minor, MD


Alexander Hardy, MBA
CEO, Genentech

Robert Bradway, MBA
Chairman and CEO, Amgen

Michelle McMurry-Heath, MD, PhD
Former President and CEO, Biotechnology Innovation Organization